Drug Profile
XR 168
Latest Information Update: 01 Aug 2002
Price :
$50
*
At a glance
- Originator Xenova Group
- Class Antirheumatics
- Mechanism of Action Collagenase inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 01 Aug 2002 Discontinued - Preclinical for Osteoarthritis in United Kingdom (unspecified route)
- 01 Aug 2002 Discontinued - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
- 09 Mar 1999 No-Development-Reported for Osteoarthritis in United Kingdom (Unknown route)